Taro to sell extended phenytoin sodium capsules for epilepsy, neurosurgery

By Elaine Rigoli

Tampa, Fla., Sept. 6 - Taro Pharmaceutical Industries Ltd. has received approval from the Food and Drug Administration for its abbreviated New Drug Application for extended phenytoin sodium capsules, USP 100 mg.

The new Taro product is bioequivalent to Pfizer's Dilantin Kapseals, used for treating seizures related to epilepsy and neurosurgery.

According to industry sources, extended-release phenytoin capsule products have annual U.S. sales of about $191 million.

Taro, based in Hawthorne, N.Y., is a science-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.